Our Approach to Schizophrenia CRO
Our elegant electrophysiological approach enables detection of translational ERP endpoints such as N1 and MMN-like responses in standard and oddball paradigm stimuli in response to test compounds, benchmarked against NMDA antagonists, (ketamine, MK-801, PCP). Furthermore, our battery of rodent cognition tests provides the opportunity for assessing whether NCEs have the potential utility for treating a range of cognitive impairments associated with schizophrenia compared to atypical antipsychotics such as clozapine.
How do we conduct our research?
Patients with schizophrenia exhibit disturbances in information processing and cognitive impairment. These disturbances are clinically investigated with different paradigms of auditory event related potentials (ERP) as well as by appropriate cognitive tests aligned to specific cognitive domains, recommended by MATRICS, CNTRIS and TURNS initiatives, which can be recapitulated in rodents.
We also offer ‘classical models’ of positive symptoms, e.g amphetamine-evoked behaviour, using our advanced LABORAS home cage monitoring system.
Disease relevant models we offer include the following:
- Mismatch negativity (MMN)
- Novel object recognition e.g. sub-chronic PCP-induced deficit
- Reversal learning
- Reversal of amphetamine/PCP-induced behaviours using LABORAS
This list is not exhaustive, we are always developing new areas of discovery within our preclinical field of expertise. If there is something particular that is not listed here please do contact us.